ViroGates AS (OCSE:VIRO) Payments of Debt: kr-1.08 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:VIRO ViroGates AS OCSE:VIRO
53 GF Score
Price kr9.50
GF Value kr6.71
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Payments of Debt?

ViroGates AS OCSE:VIRO -5.00% 53 Payments of Debt is kr-1.08 Mil as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 53/100 and a GF Value™ of kr6.71 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ViroGates AS's Payments of Debt for the three months ended in Mar. 2026 was kr-0.28 Mil.

ViroGates AS's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was kr-1.08 Mil.

ViroGates AS Payments of Debt Related Terms

ViroGates AS Payments of Debt Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Payments of Debt Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.80

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.26 -0.27 -0.28 -0.28
OCSE:VIRO
53GF Score
ViroGates AS OCSE:VIRO
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of kr-1.08 Mil mean?
ViroGates AS (OCSE:VIRO) has a Payments of Debt of kr-1.08 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on ViroGates AS and its competitors.
Is ViroGates AS's Payments of Debt too high?
ViroGates AS's current Payments of Debt is kr-1.08 Mil. Overall, ViroGates AS has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Payments of Debt compare to ABT and SYK?
ViroGates AS's Payments of Debt of kr-1.08 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on ViroGates AS and its competitors. ViroGates AS's current Payments of Debt is kr-1.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.71, compared to a current price of kr9.50 — trading 41.6% above its estimated fair value. The current Payments of Debt is kr-1.08 Mil. ViroGates AS's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Payments of Debt is kr-1.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr9.50 is trading 41.6% above its estimated GF Value™ of kr6.71. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • Payments of Debt: kr-1.08 Mil
  • GF Value™: kr6.71 vs. price of kr9.50 (41.6% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
53GF Score

Get the complete analysis for OCSE:VIRO

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.50
Price
kr6.71
GF Value